Pretty slow to start the week. Not a ton of news that would really move stocks let alone the sector. I think we are probably going to drift around in a range pretty correlated with the broader markets. While there could be some really good data that could move the sector, I still think the […]
October 18th Biotech Update
A pretty good week all things considered. Certainly a move higher this week (assuming we do not give it all back today but it does not seem that will happen). I would not say that we are in an uptrend but have moved to the upper end of what looks to be a range. I […]
October 15th Biotech Update
A good start to the week that we should ideally build upon. We are certainly heading to a period of strength for the sector (or at least should be). It was the last quarter of last year in which we got all of the gains for the year. It is setting up to be that […]
October 11th Biotech Update
Hopefully we can end the week on a high note both figuratively and literally. I still think that we probably need M&A to pick up for the sector to really catch a bid. I do not think we necessarily move lower but it really is time for some deals. Of course, the Fed was a […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
